Back to Menu
Soft tissue tumors originate from mesenchymal tissues such as adipose tissue, muscle, blood vessels, and connective tissue. They can be classified as benign, intermediate (borderline), or malignant soft tissue sarcomas. Malignant tumors are characterized by local invasiveness and the potential for distant metastasis, most commonly to the lungs.
1. Histology-based classification
Classified by tissue of origin, such as adipocytic, smooth muscle, or vascular tumors.
2. Molecular genetic classification
Classified according to genetic alterations, such as synovial sarcoma and liposarcoma, which can inform targeted therapeutic strategies.
1. Genetic factors
Hereditary cancer syndromes (e.g., Li–Fraumeni syndrome) substantially increase risk through germline mutations.
2. Environmental exposures
Long-term exposure to carcinogens such as asbestos and vinyl chloride, or prior radiotherapy, may induce sarcoma development.
3. Chronic inflammation and injury
Chronic limb lymphedema or persistent inflammation may promote certain subtypes, such as angiosarcoma.
4. Viral infection
HIV or HHV-8 infection is closely associated with the development of Kaposi sarcoma.
1. Avoidance of risk factors
Reduce exposure to chemical carcinogens, implement occupational protection, and minimize unnecessary medical radiation.
2. Regular health examinations and screening
High-risk individuals should undergo periodic imaging surveillance to enable early detection and timely intervention.
3. Healthy lifestyle
Maintain a balanced diet and regular physical activity, control body weight, and avoid chronic inflammation and repetitive injury.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that soft tissue tumors represent a heterogeneous group of diseases. While benign tumors generally have favorable outcomes, malignant sarcomas carry high risks of local recurrence and metastasis, posing a substantial threat to survival and quality of life. Implementing a multidisciplinary care model, developing individualized strategies guided by molecular classification, and strengthening screening in high-risk populations are central approaches to improving overall prognosis.
Soft tissue tumors originate from mesenchymal tissues such as adipose tissue, muscle, blood vessels, and connective tissue. They can be classified as benign, intermediate (borderline), or malignant soft tissue sarcomas. Malignant tumors are characterized by local invasiveness and the potential for distant metastasis, most commonly to the lungs.
1. Histology-based classification
Classified by tissue of origin, such as adipocytic, smooth muscle, or vascular tumors.
2. Molecular genetic classification
Classified according to genetic alterations, such as synovial sarcoma and liposarcoma, which can inform targeted therapeutic strategies.
1. Genetic factors
Hereditary cancer syndromes (e.g., Li–Fraumeni syndrome) substantially increase risk through germline mutations.
2. Environmental exposures
Long-term exposure to carcinogens such as asbestos and vinyl chloride, or prior radiotherapy, may induce sarcoma development.
3. Chronic inflammation and injury
Chronic limb lymphedema or persistent inflammation may promote certain subtypes, such as angiosarcoma.
4. Viral infection
HIV or HHV-8 infection is closely associated with the development of Kaposi sarcoma.
1. Avoidance of risk factors
Reduce exposure to chemical carcinogens, implement occupational protection, and minimize unnecessary medical radiation.
2. Regular health examinations and screening
High-risk individuals should undergo periodic imaging surveillance to enable early detection and timely intervention.
3. Healthy lifestyle
Maintain a balanced diet and regular physical activity, control body weight, and avoid chronic inflammation and repetitive injury.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that soft tissue tumors represent a heterogeneous group of diseases. While benign tumors generally have favorable outcomes, malignant sarcomas carry high risks of local recurrence and metastasis, posing a substantial threat to survival and quality of life. Implementing a multidisciplinary care model, developing individualized strategies guided by molecular classification, and strengthening screening in high-risk populations are central approaches to improving overall prognosis.